Pfizer Inc. (NYSE:PFE) Stock Has Average Target Price of $28.72 According to Analysts

Shares of Pfizer Inc. (NYSE:PFE) have earned a consensus rating of “Hold” from the twenty-one brokerages that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $28.72.

A number of equities research analysts have commented on PFE shares. BMO Capital Markets decreased their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Scotiabank raised their price target on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Finally, Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th.

Pfizer Stock Performance

Shares of PFE opened at $29.57 on Thursday. Pfizer has a 12 month low of $23.62 and a 12 month high of $29.88. The stock has a fifty day moving average price of $28.00 and a 200-day moving average price of $26.57. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm has a market cap of $168.57 billion, a PE ratio of 38.91, a P/E/G ratio of 2.01 and a beta of 0.32.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the firm earned $0.78 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.8%. Pfizer’s payout ratio is 226.32%.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in shares of Pfizer during the 2nd quarter worth about $1,049,602,000. BlackRock Inc. grew its position in shares of Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. Nykredit A S acquired a new stake in shares of Pfizer during the 2nd quarter valued at about $205,774,000. Assenagon Asset Management S.A. increased its stake in shares of Pfizer by 96.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after purchasing an additional 5,829,204 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Tukysa approval supports Pfizer’s growth outlook. The FDA’s approval of a new Tukysa regimen has strengthened the case for Pfizer’s oncology portfolio and helped drive the stock’s recent move to a 52-week high. Pfizer Stock Hits 52-Week High: What’s Going On?
• Positive Sentiment: Income appeal remains a major support. Pfizer declared its 352nd consecutive quarterly dividend, with the yield estimated at roughly 6%. The attractive payout and a forward P/E below AbbVie’s could appeal to value and income investors, assuming cash flow remains sufficient to fund the dividend. Pfizer Just Declared Its 352nd Straight Quarterly Dividend
• Positive Sentiment: Sector rotation has provided additional momentum. Buying has moved toward healthcare and away from technology, with Pfizer edging higher alongside other pharmaceutical and biotechnology stocks. Moderna Rallies as Money Rotates Into Healthcare
• Neutral Sentiment: Pfizer’s pipeline is central to the investment case. New drugs in development could help offset upcoming patent cliffs, but the company’s ability to replace lost revenue remains uncertain. Pfizer vs. AbbVie
• Negative Sentiment: Pfizer halted a Phase 2 ITP trial for PF-06835375. Termination of the mid-stage study removes one potential pipeline opportunity and highlights clinical-development risk. Pfizer Halts Mid-Stage ITP Trial
• Negative Sentiment: Investors expect a double-digit decline in third-quarter profit. Anticipated earnings pressure, combined with significant patent expirations this year and next, could limit further upside and raise questions about the sustainability of Pfizer’s dividend. What to Expect From Pfizer’s Q3 2026 Earnings Report

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.